Siewert Type II Adenocarcinoma of Esophagogastric Junction

3

Review clinical trials related to Siewert Type II Adenocarcinoma of Esophagogastric Junction. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Immediate and Functional Results of Different Types of Reconstructions After Proximal Gastrectomy For Gastric and Esophagogastric Junction Cancer

Proximal gastric and esophagogastric junction cancers comprise up to 40% of gastric malignancies. For localized disease, proximal gastrectomy is the main radical procedure, but reconstruction of GI tract often leads to significant functional issues. Rising use of proximal resections and broader indications have increased attention to postoperative quality of life (QoL). Common reconstructions include direct esophagogastrostomy (various types), double-tract reconstruction, jejunal interposition, and newer anti-reflux anastomoses (e.g., double-flap, overlap, tunnel techniques). Each method has unique pros and cons regarding reflux esophagitis, food passage, dumping syndrome, nutritional changes, and long-term QoL. No consensus exists on the optimal technique, leading to variable practices and outcomes. Most research focuses on oncologic radicality and survival, while functional results and QoL remain understudied. Systematic evaluation of functional outcomes across reconstruction types after proximal subtotal gastrectomy is needed in Russian Federation to improve QoL, advance research, and standardize treatment of proximal gastric and EGJ cancers.

Participants needed: 400
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: P. Herzen Moscow Oncology Research InstituteUpdated: Apr 22, 2026Locations: 1
Eligibility criteria

All consecutive patients with clinically documented primary Gastric or Esophagog...

Patients with clinical evidence of metastatic disease, including positive perito... [+4]

Status: Recruiting

Comparison of Different Operations for Siewert Type II Adenocarcinoma of Esophagogastric Junction

The incidence of esophagogastric junction has been increasing in recent years, and surgery is an important method for the treatment of adenoma at the esophagogastric junction. Currently, there is a great controversy about the surgical method of Siewert II, mainly choosing the right chest or the left chest for thoracic surgery. Therefore, it is of great significance to further study the surgical methods of Siewert II esophagogastric junction adenoma. Objective: To compare the safety, feasibility, and clinical efficacy of endoscopic Ivor-Lewis versus laparoscopic extended abdominal gastrectomy for Siewert type Ⅱadenocarcinoma at the resectable esophagogastric junction.

Participants needed: 212
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: Xijing Hospital of Digestive DiseasesUpdated: Nov 8, 2024Locations: 1
Eligibility criteria

Histologically confirmed EGJ type II adenocarcinoma [+8]

Histologically confirmed EGJ type I and III adenocarcinoma [+18]

Status: Recruiting

Right Versus Left Thoracic Surgical Approaches for Siewert II Gastroesophageal Junction Adenocarcinoma

To explore the 5-year overall survival (OS) of right versus left thoracic surgical approaches for patients with locally advanced Siewert II gastroesophageal junction adenocarcinoma treated by neoadjuvant chemotherapy

Participants needed: 236
Trial details
Age: 18-80Biological sex: AllType: InterventionalSponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesUpdated: Oct 16, 2024Locations: 1
Eligibility criteria

Histologically confirmed gastroesophageal adenocarcinoma; [+8]

Have a history of other malignant tumors in the past or at the same time; [+8]